Effective April 22, 2024, the AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey (collectively, AmeriHealth) and AmeriHealth Administrators Dosage and Frequency Program will expand to include five new drugs.
The following drugs will be added to this program:
- Lamzede® (velmanase alfa-tycv)
- Elfabrio® (pegunigalidase alfa-iwxj)
- Pombiliti™ (cipaglucosidase alfa-agta)
- Uptravi® IV (selexipag)
The following drugs will be removed from this program:
- Kanjinti™ (trastuzumab-anns)
- Mvasi™ (bevacizumab-awwb)
- Trazimera® (trastuzumab-qyyp)
- Zirabev™ (bevacizumab-bvzr)
These drugs have been removed from the program but will continue to be eligible for coverage under the medical benefit for members who meet the medical necessity criteria in our medical policy.
Learn more
During the precertification process, AmeriHealth and AmeriHealth Administrators ensure that the requested regimen for any drug on this program will be administered in accordance with the dosage and frequency approved by the U.S. Food and Drug Administration (FDA) or company-recognized compendia. For more information on each drug's dosage and frequency guidelines, please refer to the medical policy for the specific drug. To access these policies, visit our Medical and Claim Payment Policy Portal.
Resources
For more information, including the complete list of all 87 drugs on this program, visit our Dosage and Frequency Program webpages:
AmeriHealth
AmeriHealth Administrators